The vision of AcelaBio is to improve patient health by delivering innovative histopathology and precision medicine services that are supported by our commitment to people, process, and global partnerships.

Investing in people, facilities, technology and research that meet today and tomorrow’s regulatory standards.
Providing expert guidance on optimal processes to implement histopathology & precision medicine in multi-center clinical trials.
Enhancing global partnerships to develop new disease activity and biomarker assessments that enable efficient drug development and diagnoses.

AcelaBio provides end-to-end histopathology and precision medicine services from "sample-to-score" for clinical trials and clinical research, including:

  • Accessioning
  • Whole Slide Imaging
  • Data Management
  • Immunostaining
  • Antibody Optimization
  • Embedding
  • Hematoxylin & Eosin
  • Storage & Archiving
  • Whole Slide Imaging
  • Pathology Review
  • Sample Logistics
  • Consulting
  • Processing
  • Sectioning
  • Special Stains
  • Assay Development
Therapeutic Areas
We focus on histopathology and precision medicine for gastrointestinal diseases including, but not limited to, inflammatory bowel disease (IBD), nonalcoholic steatohepatitis (NASH), eosinophilic diseases (EoX), and celiac disease (CeD).
More on Therapeutic Areas
Please find a full directory of our current opportunities below. If you do not currently see a position of interest, please visit our contact us page and send over your resume.
Current Opportunities
Take a look at our news section to view our latest announcements, research findings, and company initiatives.
Alimentiv Health Trust Launches AcelaBio (US) Inc. Today
Read More
Implementation of Histopathology in GI Clinical Trials
Read More
Precision Medicine in IBD – From Clinical Research to Clinical Practice
Read More